ACG: Noninvasive Multitarget Stool RNA Test Has High Sensitivity for CRC
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 24, 2023 -- A noninvasive, multitarget stool RNA (mt-sRNA) test has high sensitivity for detecting colorectal neoplasia, according to a study published online Oct. 23 in the Journal of the American Medical Association to coincide with the annual meeting of the American College of Gastroenterology, held from Oct. 20 to 25 in Vancouver, British Columbia, Canada.
Erica K. Barnell, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a phase 3 clinical trial to assess the sensitivity and specificity of a noninvasive mt-sRNA test (ColoSense) compared with results from colonoscopy. A total of 8,920 participants were identified; all completed the mt-sRNA test, which included a fecal immunochemical test (FIT), concentration of eight RNA transcripts, and participant-reported smoking status. Stool samples were collected before completion of colonoscopy. The results from mt-sRNA were compared to the index lesions seen on colonoscopy. Patients aged 45 years and older were enrolled from 49 U.S. states; colonoscopies were obtained at more than 3,800 different endoscopy centers.
The researchers found that 0.40 percent of the eligible patients had colorectal cancer and 6.8 percent had advanced adenomas. The sensitivity of the mt-sRNA test for detecting colorectal cancer and advanced adenomas was 94 and 46 percent, respectively; specificity for no lesions on colonoscopy was 88 percent. Compared with results of the FIT, significant improvement in sensitivity was seen for the mt-sRNA test for colorectal cancer (94 versus 78 percent) and advanced adenomas (46 versus 29 percent).
"The mt-sRNA test can be an effective noninvasive test that is sensitive for colorectal cancer and advanced adenomas, with a comparable level of false-positive results compared with existing molecular screening tests," the authors write.
Several authors disclosed ties to medical device companies, including Geneoscopy, which developed ColoSense and funded the clinical trial.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.